Name variants collapsed into this sponsor (10)
- Centre Hospitalier Universitaire De La Reunion
- Centre Hospitalier Universitaire De Lille
- Centre Hospitalier Universitaire De Limoges
- Centre Hospitalier Universitaire De Montpellier
- Centre Hospitalier Universitaire De Nantes canonical
- Centre Hospitalier Universitaire De Nice
- Centre Hospitalier Universitaire De Nimes
- Centre Hospitalier Universitaire De Poitiers
- Centre Hospitalier Universitaire De Rennes
- Centre Hospitalier Universitaire De Toulouse
187
Registered trials
101
Recruiting
43
Completed trials
6
Countries active
284
Unique IMPs
100%
Results reported
Oversight events:
1 serious breach
6 temporary halts
1 urgent safety measure
1 corrective measure
across 9 trials
View oversight register →
100%
43 of 43 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).
Top indications
Top IMPs
SODIUM CHLORIDE
9
TACROLIMUS
5
MYCOPHENOLATE MOFETIL
4
AMOXICILLIN, CLAVULANIC ACID
3
BORTEZOMIB
3
CLOSTRIDIUM BOTULINUM NEUROTOXIN TYPE A (150KD), FREE OF COMPLEXING PROTEINS
3
ISATUXIMAB
3
KETAMINE HYDROCHLORIDE
3
LENALIDOMIDE
3
MYCOPHENOLIC ACID
3
N,N-DIETHYL-(2-(4-(2-(18F)FLUOROETHOXY)PHENYL)-5,7-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDINE-3-YL)ACETAMIDE
3
OXYGEN
3
All trials
187 total-
RAPAMALYMPH protocol Pending
Showing 1–24 of 187 trials